Connecticut Children's Medical Center
84
20
23
51
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.0%
5 terminated/withdrawn out of 84 trials
91.1%
+4.6% vs industry average
8%
7 trials in Phase 3/4
20%
10 of 51 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (84)
Pediatric Speech Therapy Session Frequency and Speech Outcomes
Role: lead
Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease
Role: lead
Interoceptive Awareness and Function in Adolescents With Chronic Pain
Role: lead
Quality of Life in Pediatric Patients With Acute Lymphoblastic Leukemia Receiving Maintenance Chemotherapy
Role: lead
Prospective Multisite Study of Quality of Life in Pediatric Intestinal Failure
Role: collaborator
Easing Scan Anxiety in Pediatric Oncology Caregivers Through Meditation-based Programs
Role: collaborator
Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage Disease
Role: lead
Accuracy of Lactate Meter in GSDIa
Role: lead
Digital Health Psychosocial Intervention for Adolescent Spine Surgery Preparation and Recovery
Role: collaborator
Assessing Post-operative Outcomes After Children's Sistrunk Procedure With or Without a Drain
Role: collaborator
ATOMIC Mobile App to Increase Physical Activity (PA) Levels in Survivors of Childhood Cancer
Role: lead
The Impact of Blood Flow Restriction Training in Adolescents After ACL Reconstruction: A Randomized Controlled Trial
Role: lead
Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy
Role: lead
Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
Role: lead
Video Discharge Instructions for Fever and ED Recidivism
Role: lead
Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy
Role: lead
Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others
Role: collaborator
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
Role: collaborator
Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity
Role: lead
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
Role: lead